Off Patent
June 2026

Aplenzin

bupropion hydrobromide

Bausch Health US LLC

Tablet, extended release (oral) · NDA 022108

Last listed protection ended
June 27, 2026

The FDA listed 8 patents for Aplenzin, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,241,805
    Claims the drug product
  2. Ended
    Patent 7,569,610
    Claims a use (U-997)
  3. Ended
    Patent 7,572,935
    Claims the drug product
  4. Ended
    Patent 7,585,897
    Claims the drug product
  5. Ended
    Patent 7,645,802
    Claims the drug product
  6. Ended
    Patent 7,649,019
    Claims the drug product
  7. Ended
    Patent 7,662,407
    Claims the drug product
  8. Ended
    Patent 7,671,094
    Claims the drug product